New combo targets KRAS lung cancer in patients who Can't have surgery
NCT ID NCT07638878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or metastatic cancer that cannot be removed with surgery. The main goal is to see how many patients' tumors shrink significantly after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab combined with albumin-bound paclitaxel and platinum chemotherapy
What this could lead to
If successful, this could offer a new treatment option for people with KRAS-mutated lung cancer who cannot have surgery, potentially shrinking tumors and extending survival.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China